Search Results - "Pileckyte, Margarita"

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis by Fleischmann, Roy M, Alten, Rieke, Pileckyte, Margarita, Lobello, Kasia, Hua, Steven Y, Cronenberger, Carol, Alvarez, Daniel, Bock, Amy E, Sewell, K Lea

“…This double-blind, randomized, 78-week study evaluated the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of PF-06410293, a candidate…”
Get full text

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis by Akhmetshina, Alfiya, Dees, Clara, Pileckyte, Margarita, Maurer, Britta, Axmann, Roland, Jüngel, Astrid, Zwerina, Jochen, Gay, Steffen, Schett, Georg, Distler, Oliver, Distler, Jörg H.W

“…Abelson kinase (c-abl) and platelet-derived growth factor (PDGF) are key players in the pathogenesis of systemic sclerosis (SSc). The aim of the present study…”
Get full text

Transcription Factor Fos-Related Antigen-2 Induces Progressive Peripheral Vasculopathy in Mice Closely Resembling Human Systemic Sclerosis by MAURER, Britta, BUSCH, Nicole, JÜNGEL, Astrid, PILECKYTE, Margarita, GAY, Renate E, MICHEL, Beat A, SCHETT, Georg, GAY, Steffen, DISTLER, Jörg, DISTLER, Oliver

“…Microvascular damage is one of the first pathological changes in systemic sclerosis. In this study, we investigated the role of Fos-related antigen-2 (Fra-2),…”
Get full text

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results by Weinblatt, Michael E, Baranauskaite, Asta, Dokoupilova, Eva, Zielinska, Agnieszka, Jaworski, Janusz, Racewicz, Artur, Pileckyte, Margarita, Jedrychowicz-Rosiak, Krystyna, Baek, Inyoung, Ghil, Jeehoon

“…The 24-week equivalent efficacy and comparable safety results of the biosimilar SB5 and reference adalimumab (ADA) from the phase III randomized study in…”
Get full text

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis by Weinblatt, Michael E., Baranauskaite, Asta, Niebrzydowski, Jaroslaw, Dokoupilova, Eva, Zielinska, Agnieszka, Jaworski, Janusz, Racewicz, Artur, Pileckyte, Margarita, Jedrychowicz‐Rosiak, Krystyna, Cheong, Soo Yeon, Ghil, Jeehoon, Sokolovic, S., Mekic, M., Prodanovic, N., Gajic, B., Karaselimovic‐Dzambasovic, E., Pojskic, B., Toncheva, A., Dimitar, P., Rodina, L., Geneva‐Popova, M., Staykov, I., Stoilov, R., Podrazilova, L., Mosterova, Z., Simkova, G., Kopackova, J., Stejfova, Z., Vencovsky, J., Urbanova, Z., Janska, L., Galatíkova, D., Stropuviene, S., Sniuoliene, I., Sitek‐Ziolkowska, K., Rell‐Bakalarska, M., Kolasa, R., Daniluk, S., Sliwowska, B., Bartosik‐Twardowska, M., Brzezicki, J., Konieczny, M., Jeka, S., Choe, J., Bae, S., Kang, Y., Prystupa, L., Vyacheslav, Z., Gasanov, I., Yatsyshyn, R., Rekalov, D., Iaremenko, O., Stanislavchuk, M., Tseluyko, V.

“…Objective SB5 is a biosimilar agent for adalimumab (ADA). The aim of this study was to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity…”
Get full text

Hypoxia‐induced increase in the production of extracellular matrix proteins in systemic sclerosis by Distler, Jörg H. W., Jüngel, Astrid, Pileckyte, Margarita, Zwerina, Jochen, Michel, Beat A., Gay, Renate E., Kowal‐Bielecka, Otylia, Matucci‐Cerinic, Marco, Schett, Georg, Marti, Hugo H., Gay, Steffen, Distler, Oliver

“…Objective Insufficient angiogenesis with tissue ischemia and accumulation of extracellular matrix are hallmarks of systemic sclerosis (SSc). Based on the…”
Get full text

Src kinases in systemic sclerosis: Central roles in fibroblast activation and in skin fibrosis by Skhirtladze, Catherine, Distler, Oliver, Dees, Clara, Akhmetshina, Alfiya, Busch, Nicole, Venalis, Paulius, Zwerina, Jochen, Spriewald, Bernd, Pileckyte, Margarita, Schett, Georg, Distler, Jörg H. W.

“…Objective Src kinases are nonreceptor tyrosine kinases, which have been implicated in cytoskeletal organization and cell mobility. This study was undertaken to…”
Get full text

Rho‐associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts by Akhmetshina, Alfiya, Dees, Clara, Pileckyte, Margarita, Szucs, Gabriella, Spriewald, Bernd M., Zwerina, Jochen, Distler, Oliver, Schett, Georg, Distler, Jörg H. W.

“…Objective Rho‐associated kinases (Rock) are the major cellular mediators of Rho GTPases and play an important role in the organization of the actin…”
Get full text

Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis by Hemmatazad, Hossein, Rodrigues, Hanna Maciejewska, Maurer, Britta, Brentano, Fabia, Pileckyte, Margarita, Distler, Jörg H. W., Gay, Renate E., Michel, Beat A., Gay, Steffen, Huber, Lars C., Distler, Oliver, Jüngel, Astrid

“…Objective We have recently shown a significant reduction in cytokine‐induced transcription of type I collagen and fibronectin in systemic sclerosis (SSc) skin…”
Get full text

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis by Weinblatt, Michael E., Baranauskaite, Asta, Dokoupilova, Eva, Zielinska, Agnieszka, Jaworski, Janusz, Racewicz, Artur, Pileckyte, Margarita, Jedrychowicz‐Rosiak, Krystyna, Baek, Inyoung, Ghil, Jeehoon

“…Objective The 24‐week equivalent efficacy and comparable safety results of the biosimilar SB5 and reference adalimumab (ADA) from the phase III randomized…”
Get full text

Phase III Randomized Study of SB 5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis by Weinblatt, Michael E., Baranauskaite, Asta, Niebrzydowski, Jaroslaw, Dokoupilova, Eva, Zielinska, Agnieszka, Jaworski, Janusz, Racewicz, Artur, Pileckyte, Margarita, Jedrychowicz‐Rosiak, Krystyna, Cheong, Soo Yeon, Ghil, Jeehoon

“…Objective SB 5 is a biosimilar agent for adalimumab ( ADA ). The aim of this study was to evaluate the efficacy, pharmacokinetics ( PK ), safety, and…”
Get full text

Clinical characteristics and long-term outcomes of 35 patients with Wegener's granulomatosis followed up at two rheumatology centers in Lithuania by Dadoniene, Jolanta, Pileckyte, Margarita, Baranauskaite, Asta, Kirdaite, Gailute

“…The aim of this study was to investigate the survival of Lithuanian patients with Wegener's granulomatosis, who were followed up at two tertiary rheumatology…”
Get full text

Severe vancomycin-induced anaphylactic reaction by Kupstaite, Rūta, Baranauskaite, Asta, Pileckyte, Margarita, Sveikata, Audrius, Kadusevicius, Edmundas, Muckiene, Gintare

“…Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as…”
Get full text

A rare case of differential diagnosis of myopathy by Pileckyte, Margarita

“…Relationship among thyroid dysfunction and musculoskeletal symptoms has been known for years. Autoimmunic thyroiditis is the most common cause of hypothyrosis…”
Get more information

Erythema nodosum association with malignant lymphoma by Pileckyte, Margarita, Griniūte, Rasa

“…Erythema nodosum is the most frequent clinicopathological variant of the panniculitides. The disorder is a cutaneous reaction consisting of inflammatory…”
Get more information

Paraneoplastic rheumatic syndromes by Pileckyte, Margarita, Baliūnaite, Rūta, Tamulaitiene, Valerija

“…Fifteen percent of patients with malignancy are diagnosed endocrinal, hematological, rheumatic or neuromuscular paraneoplastic syndromes. They are more common…”
Get more information